Jae Hee Cheon
연세대학교 · Biochemistry, Genetics and Molecular Biology
Jae Hee Cheon 교수의 연구실은 장내 미생물군과 대사물질이 장염증 및 염증성 장질환(IBD, 장비질성질환 등)에 미치는 영향을 중심으로 연구를 진행하고 있습니다. 특히, NF-κB 신호 경로 조절, 미생물 유래 대사물질(예: 숙신산)의 장세포 및 매크로파지로의 전달 메커니즘, 그리고 새로운 질환 활성도 평가 지표 개발에 초점을 맞추고 있습니다. 치료적 타겟으로서의 자연물 성분(예: 구글스테론)과 내시경 검사에서의 캡슐 유착 문제 등 임상적 응용도 함께 고려하고 있습니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
Guggulsterone blocks NF-kappaB signaling pathway by targeting IKK complex in IEC and attenuates DSS-induced acute murine colitis, which suggests that guggulsterone could be an attractive therapeutic option in the treatment of IBD.
Our large-scale study suggests that retention occurs infrequently during capsule endoscopy. Moreover, a retained capsule might indicate the best intervention for the offending pathology, or it may spontaneously pass in the long run, particularly in patients with less small bowel stricture.
This novel DAIBD is an easy, valid, and responsive index to assess disease activity and can be useful to physicians who treat intestinal BD.
The gut metabolite composition determined by the microbiota has paramount impact on gastrointestinal physiology. However, the role that bacterial metabolites play in communicating with host cells during inflammatory diseases is poorly understood. Here, we aim to identify the microbiota-determined output of the pro-inflammatory metabolite, succinate, and to elucidate the pathways that control transepithelial succinate absorption and subsequent succinate delivery to macrophages. We show a signific
Previously, the diagnosis and management of intestinal Behçet's disease depended upon the expertise of individual clinicians; however, more standardized medical assessments and improved treatment regimens for Behçet's disease patients are evolving.
